elacridar has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Gao, J; Lu, Y; Pan, X; Xie, F; Yin, C; Zhang, Y; Zou, H | 1 |
| Fukuda, S; Kojiro, M; Nakashima, O; Ookawa, K; Sakata, Y; Suto, K; Takahata, T; Tamura, Y; Tanaka, M; Tateishi, T; Yano, H | 1 |
2 other study(ies) available for elacridar and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.
Topics: Acridines; Animals; Carcinoma, Hepatocellular; Cell Death; Doxorubicin; Drug Delivery Systems; Drug Synergism; Endocytosis; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Nude; Nanoparticles; Neoplastic Stem Cells; Polyesters; Polyethylene Glycols; Rats, Sprague-Dawley; Stem Cell Transplantation; Stem Cells; Subcutaneous Tissue; Tetrahydroisoquinolines; Tissue Distribution; Tumor Stem Cell Assay; Vitamin E | 2018 |
Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flavanones; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Inhibitory Concentration 50; Irinotecan; Liver Neoplasms; Neoplasm Proteins; RNA, Messenger; Tetrahydroisoquinolines; Transfection | 2008 |